glp 1 and sexual dysfunction GLP-1 Side Effects: What's Common, What Helps, When to Call Your Clinician How GLP-1 Drugs Affect Libido,

BMJ Nutrition, Prevention & Health

465 The downregulation of GLP-1R expression may represent a significant contributory factor to the co-occurrence of hypertension and hyperglycemia

Otilonium bromide exhibits potent antifungal effects by blocking ergosterol plasma membrane localization and triggering cytotoxic autophagy in candida albicans

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Scientific References Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management

While the risk of hypoglycemia is low with GLP-1 receptor agonists alone, this risk increases when combined with insulin or sulfonylureas